Cambridge Heart fourth quarter total revenue decreases to $557.

Ischemia Pilot Study – The Company is actively seeking to expand the marketplace because of its MTWA technology to include undetected coronary artery disease . Ischemia can be an inadequate blood circulation to the coronary arteries and may lead to a significant cardiac event. The 176-affected person, dual site MTWA-CAD trial was a pilot research designed to determine if the Company’s MTWA testing can boost current diagnostic methods for detecting ischemia in patients with underlying coronary artery disease.Content DSI suit that bill from time one and acquired no equivalent with their customer service and instantaneous responsiveness. Wolf, Ph.D., Executive Vice President of CCGMP.

Antibe Therapeutics increases previously announced non-brokered private placement to up to $5,000,000 Antibe Therapeutics Inc. is very happy to announce, based on improved inbound demand, that the previously announced non-brokered private positioning has been increased to up to $5,000,000 on a single terms and conditions as announced in Antibe's press release dated March 21, 2014. Related StoriesExpanded make use of for IntelliCap with additional CE Mark for aspiration of fluidsLiposomal sizing and the Coulter theory: an interview with Professor Melvin E.